Want to see AGIO full AI Analyst Report?
AGIO Stock Chart & Stats
$35.14
-$0.03(-0.09%)
At close: 4:00 PM EST
$35.14
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)1.13M
Market Cap
$2.36B
Enterprise Value$1.29K
Total Cash (Recent Filing)$737.04M
Total Debt (Recent Filing)$35.74M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Jul 30, 2026EPS Estimate
-1.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.25
Shares Outstanding59,471,607
10 Day Avg. Volume1,001,855
30 Day Avg. Volume1,126,498
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.33Price Target Upside11.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.22
Revenue Forecast (FY)$119.34M
Bulls Say, Bears Say
Bulls Say
Strong Commercial Growth And Launch ExecutionSustained double‑digit revenue growth and rapid prescription pickup for a newly launched specialty product indicate product‑market fit and effective commercial capabilities. Durable launch execution across REMS and specialty channels improves odds of scaling revenues and absorbing fixed commercialization costs over the next 2–6 months.
High Gross MarginsVery high gross margins reflect low incremental cost to supply oral therapies and give the company structural leverage as sales grow. This margin profile supports reinvestment in R&D and commercialization, improving the path to durable operating leverage if revenue scale continues to build.
Conservative Balance Sheet And Ample LiquidityA cash runway exceeding $1B combined with minimal debt provides structural financing flexibility to fund ongoing trials, commercial expansion, and potential delays without immediate dilutive capital raises. Low leverage reduces refinancing risk and supports disciplined execution over the medium term.
Bears Say
Large And Persistent Cash BurnSustained negative operating and free cash flow of several hundred million annually creates structural financing risk if revenue ramp slows. Continued burn will require careful capital management or future financing, which can dilute shareholders or constrain strategic optionality over the coming quarters.
Deep Negative Profitability And Earnings VolatilityVery large negative operating margins and inconsistent profitability weaken return generation and shareholder value creation. Until operating costs are more consistently covered by product revenue, negative ROE and equity erosion risk will persist, complicating long‑term financial stability.
Clinical And Regulatory Uncertainty For Key ProgramsAccelerated approval paths and unexpected PK findings introduce structural execution risk: confirmatory trials and dose investigations can delay commercial expansion, raise development costs, and reduce probability of full label access, affecting long‑term revenue realization for core indications.
Agios Pharma News
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $2.36B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Apr 29, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.803 by $0.113.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.66.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 59,471,607 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.803. Following the earnings report the stock price went up 13.105%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.33 (11.93% Upside)
$39.33 (11.93% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 388.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.82%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO Stock 12 Month Forecast
Average Price Target
$39.33
▲(11.93% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
1.16% Insiders
26.35% Mutual Funds
0.37% Other Institutional Investors
52.12% Public Companies and
Individual Investors